中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2014年
35期
15-16
,共2页
西他滨%顺铂%奈达铂%复发转移性乳腺癌
西他濱%順鉑%奈達鉑%複髮轉移性乳腺癌
서타빈%순박%내체박%복발전이성유선암
Decitabine%Cisplatin%Nedaplatin%Recurrent metastatic breast cancer
目的：研究西他滨联合顺铂和吉西他滨联合奈达铂治疗复发转移性乳腺癌的临床疗效。方法：回顾性分析笔者所在医院2008年1月-2014年1月收治的70例复发转移性乳腺癌患者的病历资料，并根据患者的治疗方案情况将其随机分为试验组和对照组各35例。试验组采用西他滨联合顺铂进行治疗，对照组采用吉西他滨联合奈达铂进行治疗。观察比较4个疗程后两组患者的临床疗效及不良反应发生情况。结果：经4个疗程后，试验组的治疗总有效率为48.57%，对照组的治疗总有效率为45.71%，两组的治疗总有效率比较差异无统计学意义(P>0.05)。试验组发生Ⅲ级白细胞下降2例，Ⅲ级血小板减少1例，Ⅰ度肾损害1例，Ⅱ度肾损害6例，胃肠道反应19例；对照组发生Ⅲ级白细胞下降1例，Ⅰ度肾损害1例，Ⅱ度肾损害0例，胃肠道反应2例；试验组的Ⅱ度肾损害和胃肠道反应发生率均明显高于对照组，差异均有统计学意义(P<0.05)。结论：西他滨联合顺铂和吉西他滨联合奈达铂治疗复发转移性乳腺癌的临床疗效相当，值得在临床中广泛推广。
目的：研究西他濱聯閤順鉑和吉西他濱聯閤奈達鉑治療複髮轉移性乳腺癌的臨床療效。方法：迴顧性分析筆者所在醫院2008年1月-2014年1月收治的70例複髮轉移性乳腺癌患者的病歷資料，併根據患者的治療方案情況將其隨機分為試驗組和對照組各35例。試驗組採用西他濱聯閤順鉑進行治療，對照組採用吉西他濱聯閤奈達鉑進行治療。觀察比較4箇療程後兩組患者的臨床療效及不良反應髮生情況。結果：經4箇療程後，試驗組的治療總有效率為48.57%，對照組的治療總有效率為45.71%，兩組的治療總有效率比較差異無統計學意義(P>0.05)。試驗組髮生Ⅲ級白細胞下降2例，Ⅲ級血小闆減少1例，Ⅰ度腎損害1例，Ⅱ度腎損害6例，胃腸道反應19例；對照組髮生Ⅲ級白細胞下降1例，Ⅰ度腎損害1例，Ⅱ度腎損害0例，胃腸道反應2例；試驗組的Ⅱ度腎損害和胃腸道反應髮生率均明顯高于對照組，差異均有統計學意義(P<0.05)。結論：西他濱聯閤順鉑和吉西他濱聯閤奈達鉑治療複髮轉移性乳腺癌的臨床療效相噹，值得在臨床中廣汎推廣。
목적：연구서타빈연합순박화길서타빈연합내체박치료복발전이성유선암적림상료효。방법：회고성분석필자소재의원2008년1월-2014년1월수치적70례복발전이성유선암환자적병력자료，병근거환자적치료방안정황장기수궤분위시험조화대조조각35례。시험조채용서타빈연합순박진행치료，대조조채용길서타빈연합내체박진행치료。관찰비교4개료정후량조환자적림상료효급불량반응발생정황。결과：경4개료정후，시험조적치료총유효솔위48.57%，대조조적치료총유효솔위45.71%，량조적치료총유효솔비교차이무통계학의의(P>0.05)。시험조발생Ⅲ급백세포하강2례，Ⅲ급혈소판감소1례，Ⅰ도신손해1례，Ⅱ도신손해6례，위장도반응19례；대조조발생Ⅲ급백세포하강1례，Ⅰ도신손해1례，Ⅱ도신손해0례，위장도반응2례；시험조적Ⅱ도신손해화위장도반응발생솔균명현고우대조조，차이균유통계학의의(P<0.05)。결론：서타빈연합순박화길서타빈연합내체박치료복발전이성유선암적림상료효상당，치득재림상중엄범추엄。
Objective:To study the clinical effects of Decitabine plus Cisplatin and Gemcitabine plus Nedaplatin in the treatment of recurrent metastatic breast cancer.Method:The clinical data of 70 patients with recurrent metastatic breast cancer admitted to our hospital from January 2008 to January 2014 were retrospectively analyzed.According to the different treatment of patients,they were randomly divided into the experimental group and the control group, 35 cases in each group.The experimental group was treated with Decitabine plus Cisplatin,and the control group was treated with Gemcitabine plus Nedaplatin. The clinical effect and adverse reaction after four courses between the two groups were observed and compared.Result:After the four courses,the total effective rate of experimental group was 48.57%,and the total effective rate of control group was 45.71%,there was no statistically significant difference in total effective rate between the two groups(P>0.05).Two cases occurred decrease of white blood cells inⅢdegree,1 case occurredⅢdegree thrombocytopenia,1 case occurredⅠdegree renal injury,six cases occurredⅡdegree renal injury and nineteen cases occurred gastrointestinal tract reaction in the experimental group.In the control group,1 case occurred decrease of white blood cells inⅢdegree,two cases occurredⅠdegree renal injury,nobody occurredⅡdegree renal injury,and two cases occurred gastrointestinal tract reaction.TheⅡdegree renal injury and gastrointestinal tract reaction of experimental group were significantly higher than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The clinical effects of Decitabine plus Cisplatin and Gemcitabine plus Nedaplatin in the treatment of recurrent metastatic breast cancer are equivalent,is worth in clinical promotion.
